January Webinar: Edoxaban for the Treatment of Cancer-Associated VTE

Tuesday, January 9, 2018 1:00 PM ET

Guest Author: David Garcia, MD
Presenter: Adam Cuker, MD

VTE is a common complication of cancer and its therapy. Treatment of cancer-associated VTE is challenging, and the risks of recurrent thrombosis and bleeding are higher among patients with cancer than among those without cancer. These two complications are important because they contribute to mortality and morbidity and may interfere with cancer treatment and increase the risk of hospitalization.

The efficacy and safety of direct oral anticoagulants as compared with long-term low-molecular-weight heparin for the treatment of cancer-associated VTE have not been established. The Hokusai VTE Cancer trial was conducted to compare the oral factor Xa inhibitor edoxaban with subcutaneous dalteparin for the treatment of patients with cancer-associated VTE.

REGISTER NOW

ACE: Clinical Pearls and FAQs

Our new Clinical Pearls and FAQs section addresses questions most frequently asked by practitioners at our Boot Camp meetings including cases with complex dosing and perioperative issues. Each question is answered including links to evidence-based information for more in-depth explanations.

Click the FAQs tab to get detailed information on how to become a Center of Excellence. Learn
 specifics about how to get a copy of the assessment and why you should consider trying the assessment on behalf of your anticoagulation in or outpatient practice.

This compact 2-day meeting provides a comprehensive curriculum that covers the essential aspects of anticoagulation, disease state, and drug management. Engaging discussion around quality improvement, new agents and special situations will benefit all practitioners and daily “chalk talks” will allow for attendee participation to shape the topics.

**Transitions of Care Summit**
We have added more than 4 hours of content focusing on Transitions of Care including highlights of innovative programs, patient case studies and ideas for practice improvement in all aspects of patient transition.

**4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America**
March 8-10, 2018 | Marriott Marquis | San Diego, CA

The Thrombosis and Hemostasis Societies of North America (THSNA) will hold its 4th comprehensive scientific meeting dedicated to thrombosis and hemostasis issues in San Diego, CA from March 8-10, 2018 with pre-conference sessions held on March 7. Learn more about the conference and *pre-summit workshops*. Register by January 8, 2018 to take advantage of the registration discount.

Follow us on twitter and Facebook @AnticoagForum
Earn CE Credits on the Go

Have you visited ACForum.MinuteCE? It’s an ideal way to visit top presentations from the meeting, and stay current with the latest research and clinical advancements. Even if you attended the meeting you can receive additional CME credits for taking the on-line course.

Program Highlights: Spotlight on VTE

2016 Update of ACCP Treatment of VTE Guidelines
Clive Kearon, MB, MRCPI, FRCPC, PhD

Duration of Therapy For Venous Thromboembolism
Michael Streiff, MD, FACP

DOACs in Special Populations and Special Situations: VTE Treatment in Patients With APA and With Malignancy
Ann Wittkowsky, PharmD, CACP, FASHP, FCCP

Understanding Decision-Making Regarding Anticoagulation in Atrial Fibrillation: International Physician Survey

The Thrombosis Academy for Learning Education and Networking Training (TALENT) educational programme is conducting an international survey regarding factors that influence physician decisions to prescribe oral anticoagulation in atrial fibrillation. The dual aim of this survey is to provide better insight into the factors influencing the underutilization of oral anticoagulants in patients at high thromboembolic risk and overutilization of oral anticoagulants in patients at low thromboembolic risk for whom the risks of anticoagulation are thought to outweigh the benefits.

For further information regarding this study, please contact Dr. Deborah Siegal, North America, (siegald@mcmaster.ca), or Dr. Frederik Verbrugge, Europe, (Frederik.Verbrugge@zol.be).
The survey will take approximately 5 to 10 minutes to complete.

The study team
John Camm, St. George's University of London (London, UK)
Antonio Fiarresga, Hospital Lusíadas Lisboa (Lisbon, Portugal)
Keith Fox, University of Edinburgh (Edinburgh, UK)
Anne-Céline Martin, Hôpital Val de Grâce (Sorbonne Paris Cité, France)

Rivaroxaban and Apixaban Remain Preferred Brands Under Aetna Medicare Formularies

In early October 2017, letters were sent to some patients and providers from Aetna and Coventry Healthcare-Medicare Advantage Plan indicating that rivaroxaban (Xarelto) would not be a preferred brand in 2018. This decision has since been reversed and rivaroxaban (Xarelto) will remain a preferred brand along with apixaban (Eliquis) across all of Aetna's Part D formularies. Aetna's Medicare online formulary will be updated shortly to reflect this change; however, providers should be aware of the decision reversal should they get questions from patients. Find more information here.

Find out more about Anticoagulation Forum

acforum.org

The Anticoagulation Forum is a multi-disciplinary nonprofit organization of healthcare professionals that will improve the quality of care for patients taking antithrombotic medications

Not a member yet? Join us (it's free!) at acforum.org
Follow us on twitter and Facebook @AnticoagForum

Thank You to Our Newsletter Sponsors